Novartis Pharmaceuticals Corp
- All
- News
-
Novartis Acquires US Pharma Firm Selexys Pharmaceuticals
Selexys specialises in sickle cell disease, an inherited form of anaemia that is most common among people of African descent.
-
US sues Novartis over kickbacks, second case this week
The US government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.
-
US sues Novartis, alleging kickbacks to pharmacies
U.S. Attorney Preet Bharara in Manhattan said Novartis had since 2005 induced at least 20 pharmacies to switch thousands of kidney transplant patients to its immunosuppressant drug Myfortic from competitors' drugs, in exchange for kickbacks disguised as rebates and discounts.
-
US lawsuit accuses Novartis of health care fraud
The US government sued Novartis Pharmaceuticals Corp. Tuesday, claiming it gave kickbacks to pharmacies to switch kidney transplant patients from competitors' drugs to its own.
-
Novartis Acquires US Pharma Firm Selexys Pharmaceuticals
Selexys specialises in sickle cell disease, an inherited form of anaemia that is most common among people of African descent.
-
US sues Novartis over kickbacks, second case this week
The US government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.
-
US sues Novartis, alleging kickbacks to pharmacies
U.S. Attorney Preet Bharara in Manhattan said Novartis had since 2005 induced at least 20 pharmacies to switch thousands of kidney transplant patients to its immunosuppressant drug Myfortic from competitors' drugs, in exchange for kickbacks disguised as rebates and discounts.
-
US lawsuit accuses Novartis of health care fraud
The US government sued Novartis Pharmaceuticals Corp. Tuesday, claiming it gave kickbacks to pharmacies to switch kidney transplant patients from competitors' drugs to its own.
